Biogen (BIIB) Enterprise Value (2009 - 2026)
Biogen (BIIB) posted quarterly Enterprise Value of -$1.3 billion for Q2 2026, up 53.42% year-over-year from -$837.6 million in Q2 2025, and up 70.0% quarter-over-quarter from -$4.3 billion in Q1 2026.
Biogen (BIIB) Enterprise Value (2009 - 2026) Analysis & Trends
Biogen's Enterprise Value history runs 18 years deep, the most recent figure standing at -$1.3 billion for Q2 2026.
- In Q2 2026, Enterprise Value rose 53.42% year-over-year to -$1.3 billion; the TTM figure through Jun 2026 stood at -$1.3 billion (up 53.42% YoY), while the FY2025 annual figure was -$3.8 billion, down 60.66% from the prior year.
- Enterprise Value for Q2 2026 stood at -$1.3 billion, up from -$4.3 billion in the prior quarter.
- The five-year high for Enterprise Value was -$1.0 billion in Q4 2023, with the low at -$6.1 billion in Q2 2023.
- The 5-year median for Enterprise Value is -$3.3 billion (2022), against an average of -$3.3 billion.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value surged 78.73% in 2024, then slumped 141.84% in 2025.
- Biogen's Enterprise Value stood at -$4.9 billion in 2022, then surged by 78.58% to -$1.0 billion in 2023, then tumbled by 126.21% to -$2.4 billion in 2024, then plunged by 60.66% to -$3.8 billion in 2025, then soared by 66.32% to -$1.3 billion in 2026.
- Business Quant data shows BIIB's Enterprise Value at -$1.3 billion in Q2 2026, -$4.3 billion in Q1 2026, and -$3.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.77 Bn | 631.01 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 470.29 Bn | 463.72 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 374.97 Bn | 367.83 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 302.80 Bn | 295.11 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 257.17 Bn | 252.27 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 236.88 Bn | 222.89 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 182.68 Bn | 179.50 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 159.74 Bn | 148.04 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 106.06 Bn | 101.89 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -1.29 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.29 Bn |
| Mar 31, 2026 | -4.28 Bn |
| Dec 31, 2025 | -3.82 Bn |
| Sep 30, 2025 | -3.96 Bn |
| Jun 30, 2025 | -2.76 Bn |
| Mar 31, 2025 | -2.60 Bn |
| Dec 31, 2024 | -2.38 Bn |
| Sep 30, 2024 | -1.70 Bn |
| Jun 30, 2024 | -1.91 Bn |
| Mar 31, 2024 | -1.07 Bn |
| Dec 31, 2023 | -1.05 Bn |
| Sep 30, 2023 | -2.29 Bn |
| Jun 30, 2023 | -6.08 Bn |
| Mar 31, 2023 | -5.05 Bn |
| Dec 31, 2022 | -4.90 Bn |
| Sep 30, 2022 | -4.92 Bn |
| Jun 30, 2022 | -4.81 Bn |
| Mar 31, 2022 | -3.77 Bn |
| Dec 31, 2021 | -3.74 Bn |
| Sep 30, 2021 | -2.50 Bn |